Skip to main content
FULC logo

Fulcrum Therapeutics, Inc. (FULC) Stock: Price, Forecast & Analyst Target

Fulcrum Therapeutics, Inc. (FULC) — MoonshotScore 56/100 (Fair band), calculated Nov 18, 2026. Price $3.71 (-0.27%), as of the Nov 19, 2026 trading session; market cap $283M.

Educational signal · not a buy or sell recommendation · How to read this

$3.71 −$0.01 (-0.27%) Market Cap $283M

Fulcrum Therapeutics, Inc. · FULC · NASDAQ

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetically defined diseases with high unmet medical needs.

Price as of Nov 19, 2026

Key Statistics

56 of 100

MoonshotScore v2 · Fulcrum Therapeutics (FULC)

Fair
Business Quality Average (46)
Financial Safety Sound (69)
Valuation Fair (60)
Growth Durability Flat (41)
Momentum Slipping (37)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, though quality and growth are only middling. Business Quality: Average; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Slipping.

  • EPS beat 4 of the last 8 reports
  • Altman Z 16.92 · Piotroski F 2
  • ROE -30.5% · ROA -18.1% · current ratio 36.19

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for FULC (57 recorded, newest six shown)
RecordedScoreBand
50Fair
50Fair
50Fair
50Fair
56Fair
56Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.71
Change on the day-0.27%
52-week range$2.83 – $15.74
Market capitalisation$283M
Shares traded on the day682.0K

Price & events

Other perspectives

Council score for Fulcrum Therapeutics (FULC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Moderate
Valuation Moderate
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Fulcrum Therapeutics (FULC), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Fulcrum Therapeutics, Inc. (FULC) is listed on NASDAQ. It employs 9 people and is led by Alexander C. Sapir. The market values it at $283M.

2 · Latest results

What do the latest results show for Fulcrum Therapeutics (FULC)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Fulcrum Therapeutics (FULC)?

Short answer

The MoonshotScore pillars rate balance-sheet strength as strengths. The distress and quality screens read Altman Z 16.92 · Piotroski F 2. Trailing ratios: ROE -30.5% · ROA -18.1% · current ratio 36.19.

Data-derived red flags

  • Negative return on equity (-30.5%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Fulcrum Therapeutics (FULC)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $311,890 · EPS -0.60 · 5 analysts. Current published price targets run low $3.00 · high $4.00 · consensus $3.60 · median $4.00 against a quoted price of $3.71 (as of Nov 19, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for FULC.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Fulcrum Therapeutics compare with its peers?

Short answer

Fulcrum Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Fulcrum Therapeutics (FULC) — this page$3.71$283M56

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$3.00 – $4.00
Consensus target
$3.60
Median target
$4.00
Revenue estimate
$311,890
EPS estimate
$-0.60

Consensus record · Captured .

Measured against a quoted price of $3.71 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 17, 2026

Transactions
15
Identified insiders
9
Purchases
6
Sales
1
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held FULC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported FULC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: FULC Stock

These answers are editorial: 1 of these 9 answers is drawn from the FULC research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for FULC?

FULC carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is FULC a good stock to buy?

Stock Expert AI does not rate FULC buy, sell or hold. Fulcrum Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the FULC stock price today?

The last price recorded for Fulcrum Therapeutics, Inc. (FULC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the FULC price target?

The analyst consensus price target for Fulcrum Therapeutics, Inc. (FULC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for FULC?

The main risks for Fulcrum Therapeutics include clinical trial failures, regulatory hurdles, and competition from other companies developing therapies for similar indications.

What are the key factors to evaluate for FULC?

Fulcrum Therapeutics, Inc. (FULC) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company has strategic collaborations with Acceleron Pharma Inc. and MyoKardia, Inc. (now part of Bristol Myers Squibb) to expand its pipeline. Not financial advice.

How frequently does FULC data refresh on this page?

FULC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven FULC's recent stock price performance?

Fulcrum Therapeutics, Inc. (FULC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clinical-stage pipeline with promising product candidates. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider FULC overvalued or undervalued right now?

Fulcrum Therapeutics, Inc. (FULC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.